Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement

Rhea-AI Summary

Agenus has announced the cancellation of its conference call scheduled for March 13, 2023, regarding its minority cash holdings at Silicon Valley Bank (SVB). This decision follows the government's announcement concerning access to SVB deposits. Agenus is a clinical-stage immuno-oncology company focused on developing therapies that enhance the body's immune response against cancer and infections. The company's approach includes a wide array of antibody therapeutics and adoptive cell therapies. Headquartered in Lexington, MA, Agenus continues to aim for innovative cancer treatment solutions.

Positive

• The company has a robust pipeline of immuno-oncology therapies.
• Agenus invests in combination approaches to enhance cancer immunotherapy.

Negative

• Cancellation of the conference call may signal uncertainty regarding cash positions.

Conference Call Cancelled

LEXINGTON, Mass., March 12, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it has cancelled its conference call on Monday, March 13^th to discuss its minority cash holdings at Silicon Valley Bank (SVB) in light of the government’s SVB deposit access announcement.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Inc.
Zack Armen
Head of Investor Relations
917-362-1370
zack.armen@agenusbio.com

FAQ

Why did Agenus cancel its conference call on March 13, 2023?

Agenus canceled the conference call in response to the government's announcement about deposit access at Silicon Valley Bank.

What is the focus of Agenus as a company?

Agenus focuses on developing therapies that activate the immune system to combat cancer and infections.

What are Agenus's minority cash holdings related to?

The minority cash holdings are related to deposits at Silicon Valley Bank.

Where is Agenus headquartered?

Agenus is headquartered in Lexington, Massachusetts.

What are some approaches Agenus uses in its therapies?

Agenus employs a broad repertoire of antibody therapeutics and adoptive cell therapies in its treatment approaches.